Announcement • Jul 23
Serina Therapeutics, Inc. Announces Appointment of Farrell Simon to Board of Directors and Board Committees, Effective July 22, 2026 Serina Therapeutics, Inc. had announced the appointment of Farrell Simon, Pharm. D., to the Company's Board of Directors, effective July 22, 2026. Dr. Simon had also been appointed to serve as a member of the Audit Committee and Compensation Committee. Dr. Simon is a biotech, pharmaceutical and consumer health executive with expertise in commercial strategy, operations, and business development. He currently serves as Chief Commercial Officer at Trevi Therapeutics, Inc., where he leads commercial strategy, lifecycle management, and pre-commercial readiness planning. He also leads business development efforts for potential partnerships and M&A. During his tenure at Trevi, he helped engage Trevi's investor base and supported financings totaling more than $400 million from top-tier investors including Frazier, Vivo, Venrock, and Viking. Prior to Trevi, Dr. Simon spent a decade at Pfizer in a series of senior commercial and strategic leadership roles, including Biopharma Chief of Staff and global commercial leadership positions supporting major brands and pipeline assets. He holds a Doctor of Pharmacy degree and an MBA, with a concentration in Finance, from the University of Florida. Announcement • Jul 09
Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson’s Disease Serina Therapeutics, Inc. announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease. Following review of initial 72-hour safety and tolerability observations from the sentinel dosing group, the study’s independent Safety Monitoring Committee recommended that dosing continue in the remainder of Cohort 1. Additional patient dosing in Cohort 1 is now underway across sites in the United States and Australia. Serina previously guided that completion of enrollment and dosing in Cohort 1 was expected by the end of the third quarter of 2026. Based on current site activity and patient screening and dosing, the Company now expects to complete enrollment and dosing of Cohort 1 ahead of that timeline, subject to continued trial execution. The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b registrational trial with single-ascending-dose and multiple-ascending-dose components in adults with Parkinson’s disease and motor fluctuations. The study is designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation is overseen by a Safety Monitoring Committee, and the study is being conducted across sites in Australia and the United States, with plans to bring on sites in South Korea and Taiwan as the study advances through subsequent cohorts. The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by an independent Safety Monitoring Committee, and the study is being conducted across sites in the United States, Australia with plans to South Korea and Taiwan. Serina’s proprietary POZ technology is based on a synthetic, water-soluble, low viscosity polymer called poly (2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations. SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. New Risk • May 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Negative equity (-US$37k). Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (US$130k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$34m net loss in 3 years). Market cap is less than US$100m (US$28.3m market cap). 
